Literature DB >> 24421416

Drug Monographs: Ziv-aflibercept and Vincristine Sulfate Liposome.

Jessica N Lee1, Dominic A Solimando1, J Aubrey Waddell1.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2013        PMID： 24421416      PMCID： PMC3839431          DOI： 10.1310/hpj4801-14

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  19 in total

1.  Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.

Authors:  Robert L Coleman; Linda R Duska; Pedro T Ramirez; John V Heymach; Aparna A Kamat; Susan C Modesitt; Kathleen M Schmeler; Revathy B Iyer; Michael E Garcia; Debbie L Miller; Edward F Jackson; Chaan S Ng; Vikas Kundra; Robert Jaffe; Anil K Sood
Journal:  Lancet Oncol       Date:  2011-10-10       Impact factor: 41.316

2.  Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin.

Authors:  Ahmad A Tarhini; Paul Frankel; Kim A Margolin; Scott Christensen; Christopher Ruel; Janice Shipe-Spotloe; David R Gandara; Alice Chen; John M Kirkwood
Journal:  Clin Cancer Res       Date:  2011-08-31       Impact factor: 12.531

3.  Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors.

Authors:  Nicolas Isambert; Gilles Freyer; Sylvie Zanetta; Benoît You; Pierre Fumoleau; Claire Falandry; Laure Favier; Sylvie Assadourian; Karen Soussan-Lazard; Samira Ziti-Ljajic; Veronique Trillet-Lenoir
Journal:  Clin Cancer Res       Date:  2012-01-18       Impact factor: 12.531

4.  Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients.

Authors:  Agop Y Bedikian; Anna Vardeleon; Teresa Smith; Susan Campbell; Rostam Namdari
Journal:  J Clin Pharmacol       Date:  2006-07       Impact factor: 3.126

5.  Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.

Authors:  John F de Groot; Kathleen R Lamborn; Susan M Chang; Mark R Gilbert; Timothy F Cloughesy; Kenneth Aldape; Jun Yao; Edward F Jackson; Frank Lieberman; H Ian Robins; Minesh P Mehta; Andrew B Lassman; Lisa M Deangelis; W K Alfred Yung; Alice Chen; Michael D Prados; Patrick Y Wen
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

6.  Phase I study of liposomal vincristine.

Authors:  K A Gelmon; A Tolcher; A R Diab; M B Bally; L Embree; N Hudon; C Dedhar; D Ayers; A Eisen; B Melosky; C Burge; P Logan; L D Mayer
Journal:  J Clin Oncol       Date:  1999-02       Impact factor: 44.544

7.  Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

Authors:  A Craig Lockhart; Mace L Rothenberg; Jakob Dupont; Wendy Cooper; Paul Chevalier; Lars Sternas; Giliane Buzenet; Elizabeth Koehler; Jeffrey A Sosman; Lawrence H Schwartz; David H Gultekin; Jason A Koutcher; Edwin F Donnelly; Ric Andal; Isabelle Dancy; David R Spriggs; William P Tew
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

8.  Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.

Authors:  Deborah A Thomas; Hagop M Kantarjian; Wendy Stock; Leonard T Heffner; Stefan Faderl; Guillermo Garcia-Manero; Alessandra Ferrajoli; William Wierda; Sherry Pierce; Biao Lu; Steven R Deitcher; Susan O'Brien
Journal:  Cancer       Date:  2009-12-01       Impact factor: 6.860

9.  Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study.

Authors:  M A Rodriguez; Robert Pytlik; Tomas Kozak; Mukesh Chhanabhai; Randy Gascoyne; Biao Lu; Steven R Deitcher; Jane N Winter
Journal:  Cancer       Date:  2009-08-01       Impact factor: 6.860

10.  A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors.

Authors:  Andrea Wang-Gillam; William P Tew; Mace L Rothenberg; Jakob Dupont; Wendy Cooper; Lars Sternas; Giliane Buzenet; Jeffrey A Sosman; David R Spriggs; Albert Craig Lockhart
Journal:  Invest New Drugs       Date:  2011-10-15       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.